It is the policy of the American Epilepsy Society to ensure balance, independence, objectivity, and scientific rigor. All individuals involved in the selection, development, and presentation of content are required to disclose any real or apparent conflicts of interest. Conflicts of interest will be resolved by AES prior to an educational activity being delivered to learners.
Resolutions of Conflicts of Interest
It is the policy of the American Epilepsy Society to ensure balance, independence, objectivity, and scientific rigor. All persons involved in the selection, sevelopment, and presentation of content are required to disclose any real or apparent conflicts of interest. In accordance with the ACCME Standards for Commercial Support of CME, AES implemented the mechanisms of prospective peer review of this CME activity to identify and resolve any conflicts. Additionally, the content of this activity is based on the best available evidence.
Unapproved Use Disclosure
The American Epilepsy Society requires CME authoris to disclose to learners when products or procedures being discussed are off-label, unlabeled, experimental, and/or investigational (not FDA-approved); and any limitations on the information that is presented, such as data that are preliminary or that represent ongoing research, interim analyses, and/or unsupported opinion. This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. If you have questions, contact the medical affairs department of the manufacturer for the most recent prescribing information. Information about pharmaceutical agents/devices that is outside of U.S. Food and Drug Administration approved labeling may be contained in this activity.
This CME activity is for educational purposes only and does not constitute the opinion or endorsement of, or promotion by, the American Epilepsy Society. Reasonable efforts have been taken to repsent educational subject matter in a balanced, unbiased fashion, and in compliance with regulatory requirements. However, each activity participant must always use his or her own personal and professional judgment when considering future application of this information, particularly as it may relate to patient diagnostic or treatment decisions including, without limitation, FDA-approved uses and any off-label investigational, and/or experimental uses.